Mizuho downgraded uniQure to Neutral from Buy with a price target of $10, down from $52. The firm is moving to the sidelines as it believes the current stock price fairly reflects the value for Hemgenix gene therapy for hemophilia B and is cautious about ATM-130 gene therapy in Huntington’s disease. Though the firm believes the stock price has “largely incorporated our cautiousness,” it does not have good visibility into any meaningful near-term catalysts, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on QURE:
- uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- uniQure announces inducement grants under Nasdaq listing rule
- uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
- uniQure announces FDA clearance of IND application for AMT-191 gene therapy
- uniQure expects cash to fund operations into 2Q27
